U.S. Patent 8,431,615: Scope, Claims, Expiration, and Telaprevir Patent Landscape

U.S. Patent No. 8,431,615 protects a specific combination regimen for treating hepatitis C virus infection with telaprevir, pegylated interferon, and ribavirin. The claims require telaprevir, identified in the patent as VX-950, at approximately 750 mg three times daily for at least 14 days, together with pegylated interferon at approximately 180 μg per week and ribavirin. Claim 2 narrows the dosing interval to every eight hours.

The patent is a method-of-treatment patent, not a composition-of-matter patent. Its commercial relevance arose from the dosing regimen used for Vertex Pharmaceuticals' Incivek, whose active ingredient is telaprevir. Incivek was approved by the FDA in 2011 but was later displaced by direct-acting antiviral regimens with improved tolerability, shorter treatment duration, and higher cure rates.[1]

What does U.S. Patent 8,431,615 cover?

The patent covers a therapeutic regimen with four central limitations:

Claim element	Requirement
Active antiviral	VX-950, or a pharmaceutically acceptable salt
Telaprevir dose	About 750 mg
Telaprevir frequency	Three times per day
Background therapy	Pegylated interferon plus ribavirin
Pegylated interferon dose	About 180 μg per week
Treatment duration	At least 14 days
Claim 2 limitation	Telaprevir administered every eight hours

Claim 1 is a combination-treatment claim. A practice that uses telaprevir alone does not meet the claim because pegylated interferon and ribavirin are mandatory elements. A regimen using pegylated interferon without ribavirin also falls outside the literal scope.

The phrase "for a period of at least 14 days" establishes a minimum treatment period. It does not, on its face, require a 12-week telaprevir course, a specific subsequent treatment phase, a particular hepatitis C genotype, or a defined patient-treatment history.

How should the claims be construed?

What does "about 750 mg" mean?

"About" creates a range rather than an absolute requirement of exactly 750 mg. The permitted range would ordinarily be assessed using the patent specification, prosecution history, technical context, and infringement doctrine. The claim is strongest against regimens that use the labeled 750 mg dose or a dose close to it.

A materially different dose could avoid literal infringement, although the doctrine of equivalents could become relevant. The practical scope would depend on whether the alternative dose performs substantially the same function in substantially the same way with substantially the same result.

Does three-times-daily dosing require eight-hour intervals?

Claim 1 requires administration three times per day but does not expressly require equal intervals. Claim 2 adds the specific requirement that telaprevir be administered every eight hours.

The distinction matters:

A 750 mg morning, afternoon, and evening schedule may fall within claim 1 even if the intervals are not exactly eight hours.
An every-eight-hour schedule is expressly covered by claim 2.
A twice-daily regimen does not satisfy either claim.
A regimen using 750 mg every eight hours is likely to satisfy both claims if the pegylated interferon, ribavirin, and duration limitations are also met.

Is concurrent administration required?

The claims describe a regimen comprising telaprevir, pegylated interferon, and ribavirin. The ordinary technical reading is combination therapy delivered as part of the same treatment course. The claim does not expressly require that all three agents be administered at the same moment, but a treatment sequence separated by a clinically meaningful interval could raise claim-construction issues.

The claim does not require a particular order of administration, formulation, food instruction, genotype, viral-load threshold, or sustained virologic response.

What is the legal scope of claim 1?

Claim 1 is a narrow but commercially targeted regimen claim. It is narrow because it requires all of the following:

Telaprevir rather than another HCV protease inhibitor.
Approximately 750 mg per dose.
Three administrations per day.
Pegylated interferon at approximately 180 μg weekly.
Ribavirin.
Treatment for at least 14 days.

It is commercially broad within the historical Incivek label because those limitations closely track the approved telaprevir regimen. The claim does not need to identify Incivek by brand name. Use of a generic telaprevir product could still implicate the claim if the regimen satisfies the limitations.

The claim does not cover the entire telaprevir molecule, every use of telaprevir, or every HCV treatment. It also does not cover later-generation HCV products such as sofosbuvir, ledipasvir, glecaprevir, pibrentasvir, elbasvir, grazoprevir, or combinations containing those agents.

What does claim 2 add?

Claim 2 adds an eight-hour dosing interval. It is a dependent claim and therefore incorporates every limitation of claim 1.

Scenario	Claim 1	Claim 2
Telaprevir 750 mg three times daily, peginterferon, ribavirin	Potentially covered	Potentially covered only if every eight hours
Telaprevir 750 mg every eight hours with peginterferon and ribavirin	Covered if duration is at least 14 days	Covered
Telaprevir twice daily	Not covered	Not covered
Telaprevir monotherapy	Not covered	Not covered
Telaprevir plus peginterferon without ribavirin	Not covered	Not covered
Telaprevir at a materially different dose	Potentially outside literal scope	Potentially outside literal scope

When does U.S. Patent 8,431,615 expire?

U.S. Patent 8,431,615 issued on April 30, 2013.[2] The patent is associated with Vertex's telaprevir development and claims the clinical regimen used with Incivek.

The expected patent-term endpoint is in 2027, subject to the patent's full priority chain, terminal disclaimers, patent-term adjustment, and any applicable patent-term extension. The expiration date should be taken from the USPTO patent record and current maintenance records rather than inferred solely from the issue date.[2]

The practical commercial value of the patent is lower than its nominal remaining term because Incivek was withdrawn from commercial distribution after the HCV market shifted to all-oral direct-acting antiviral therapy. Patent expiration therefore has limited effect on the current U.S. treatment market.

What was the FDA regulatory status of telaprevir?

The FDA approved Incivek, containing telaprevir, in May 2011 for use with peginterferon alfa and ribavirin in adults with chronic hepatitis C genotype 1 infection.[1] The approved regimen used telaprevir 750 mg every eight hours with food, combined with peginterferon alfa and ribavirin.

The approved product had a defined telaprevir-containing treatment phase, followed by continued peginterferon and ribavirin therapy. Patent claim 1 is broader in duration than a particular 12-week label period because it requires only at least 14 days.

Telaprevir's approval was later overshadowed by all-oral direct-acting antiviral regimens. The shift reduced the commercial importance of the telaprevir patent estate even before the principal patent terms ended.

What was the Orange Book status of U.S. Patent 8,431,615?

The relevant Orange Book question is whether the patent was listed against Incivek's NDA and whether that listing remained active after the product's withdrawal. Orange Book listings are product-specific and can change after a product is withdrawn, after patent expiration, or after FDA administrative action.[3]

Because U.S. Patent 8,431,615 is a method-of-use patent directed to the approved Incivek regimen, it was eligible in principle for Orange Book consideration if submitted by the NDA holder in accordance with FDA listing requirements. The existence of a patent does not by itself establish that it was listed, remained listed, or created a current ANDA certification obligation.

For a generic applicant, a listed method-of-use patent can generate a Paragraph IV certification if the applicant seeks approval for a use covered by the patent. An ANDA applicant can also use a section viii statement to carve out a patented method where the proposed labeling does not include the protected use.

What Paragraph IV challenges affected telaprevir?

Paragraph IV risk for telaprevir was limited by the rapid commercial decline of Incivek. A generic applicant challenging an active listed method patent would have faced several possible arguments:

The proposed regimen does not use telaprevir at approximately 750 mg.
The proposed regimen does not use telaprevir three times daily.
The product is not administered with both pegylated interferon and ribavirin.
The treatment period is less than 14 days.
The claims are anticipated or obvious in view of prior clinical studies and prescribing information.
The patent is invalid for lack of written description or enablement.
The patent is unenforceable based on prosecution conduct, if supported by the record.

The strongest validity challenge would likely focus on obviousness. The claimed regimen tracks the clinically successful and ultimately approved telaprevir regimen. The patent holder's response would rely on the claimed dose, frequency, combination, and treatment duration as a clinically selected regimen rather than an arbitrary aggregation of known parameters.

The absence of a significant current U.S. telaprevir market reduces the incentive to litigate. A patent challenge has greater economic value where the reference product generates substantial sales or where a generic launch can recover development and litigation costs.

What other patents protected telaprevir and Incivek?

The telaprevir estate included more than regimen patents. Relevant protection generally fell into four groups:

Patent category	Typical subject matter	Commercial function
Composition-of-matter patents	Macrocyclic HCV NS3/4A protease inhibitors, including telaprevir-related compounds	Core molecule protection
Pharmaceutical composition patents	Salt forms, solid forms, excipients, and dosage forms	Product and formulation protection
Manufacturing patents	Synthetic intermediates, processes, purification, and crystallization	Supply-chain and process protection
Method-of-treatment patents	Dose, schedule, combination therapy, and patient treatment	Clinical-use protection

U.S. Patent 8,431,615 belongs to the last category. It does not replace composition-of-matter protection. Its value depends on whether a competing product or label practices the claimed clinical regimen.

The patent is therefore weaker against a product that uses a different dose, a different dosing frequency, or an all-oral combination that excludes pegylated interferon and ribavirin. It is stronger against a generic telaprevir product marketed for the original Incivek regimen.

How strong is the patent estate for the claimed regimen?

The patent has moderate legal strength and limited present commercial strength.

Legal strengths

The claims identify a concrete dose and dosing schedule.
The regimen maps closely to the historical FDA-approved use.
Claim 2 provides a precise eight-hour schedule.
The patent can potentially reach use of a generic telaprevir product, not only branded Incivek.
The minimum 14-day limitation is shorter than the full historical telaprevir treatment course.

Legal weaknesses

The claims are confined to telaprevir-based therapy.
Pegylated interferon and ribavirin are mandatory.
The claims do not cover the active ingredient itself.
"About" introduces a fact-specific dosing boundary.
The regimen may face obviousness arguments based on known telaprevir clinical-development data.
The patent does not block next-generation all-oral HCV therapies.

Commercial weaknesses

Incivek sales declined as newer HCV regimens replaced interferon-based treatment. The relevant competitive risk is no longer primarily a generic substitution event. It is therapeutic displacement by newer direct-acting antiviral products with simpler administration and better tolerability.

What generic launch scenarios exist?

Scenario 1: Telaprevir ANDA with full historical labeling

A generic applicant seeking the original Incivek regimen would face the greatest exposure to the patent claims if the patent remained listed and unexpired. The applicant could file a Paragraph IV certification and challenge validity or enforceability, or wait for expiration.

Scenario 2: Section viii carve-out

An applicant could seek approval with labeling that omits the patented method, provided the remaining labeling is legally and medically supportable. This route would be difficult if the protected regimen represented the principal or only approved use.

Scenario 3: Non-infringing dosing regimen

A product using a materially different dose or dosing frequency could avoid literal infringement, but it would need regulatory support for the alternative regimen. A dosing change made solely to avoid patent coverage would not create a viable product without clinical and FDA support.

Scenario 4: No commercial launch

Given the withdrawal of Incivek and the dominance of newer HCV therapies, a generic telaprevir launch would face weak market economics even if patent barriers were removed.

What litigation and settlement issues matter?

The key litigation issues would be claim construction, obviousness, enablement, written description, and the treatment of "about 750 mg." In an ANDA case, the scope of the proposed labeling would also determine whether the applicant's product is directed to the patented method.

No settlement should be assumed from the existence of the patent. A settlement would be commercially rational only if the reference product retained meaningful demand, the generic had a credible launch opportunity, and the parties valued earlier entry. Those conditions weakened substantially after the market moved to newer HCV therapies.

Key Takeaways

U.S. Patent 8,431,615 is a method-of-treatment patent for telaprevir-based HCV therapy.
Claim 1 requires approximately 750 mg of telaprevir three times daily, pegylated interferon at approximately 180 μg per week, ribavirin, and at least 14 days of treatment.
Claim 2 specifically requires an eight-hour telaprevir dosing interval.
The patent does not cover telaprevir itself, every telaprevir use, or newer all-oral HCV products.
The expected patent-term endpoint is in 2027, subject to the official USPTO term calculation.
The claims closely track the historical Incivek regimen, giving them strong product-label relevance but narrow technical scope.
Generic risk is legally possible but commercially limited because Incivek was displaced and withdrawn from the market.
The principal legal vulnerabilities are obviousness, claim construction around "about," and the scope of any Orange Book listing.

FAQs

Does U.S. Patent 8,431,615 cover Incivek itself?

No. It covers a therapeutic regimen using telaprevir with pegylated interferon and ribavirin. Separate patents were required to protect the active compound, formulations, and manufacturing processes.

Can a generic telaprevir product infringe the patent?

Yes. Patent infringement does not depend on use of the Incivek brand. A generic product used according to the claimed regimen could create direct or induced infringement issues if the relevant claims remained enforceable.

Does a 12-week telaprevir course fall within the patent?

Yes, if the regimen otherwise satisfies the claimed dose, frequency, pegylated interferon, ribavirin, and minimum 14-day requirements. The claims do not impose a maximum treatment duration.

Does claim 2 require exactly 24-hour cycles?

Claim 2 requires administration every eight hours. In clinical and legal analysis, the exact meaning of an administration interval would depend on the prescribing instructions, actual use, and claim construction.

Are biosimilars relevant to telaprevir?

No. Telaprevir is a chemically synthesized small molecule. The relevant regulatory pathway for a competing product would generally be the ANDA pathway for a generic drug, not the FDA's 351(k) biosimilar pathway.

References

U.S. Food and Drug Administration. (2011). Incivek (telaprevir) prescribing information. FDA.
United States Patent and Trademark Office. (2013). U.S. Patent No. 8,431,615, methods for treating hepatitis C virus infection. USPTO.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
Vertex Pharmaceuticals Incorporated. (2013). Annual report on Form 10-K for the fiscal year ended December 31, 2012. U.S. Securities and Exchange Commission.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Vertex Pharms	INCIVEK	telaprevir	TABLET;ORAL	201917-001	May 23, 2011		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				METHOD OF TREATING CHRONIC HEPATITIS C	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2005302361	⤷ Start Trial
Canada	2585647	⤷ Start Trial
China	101068547	⤷ Start Trial
China	102988365	⤷ Start Trial
European Patent Office	1819336	⤷ Start Trial
European Patent Office	2500021	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,431,615

Which drugs does patent 8,431,615 protect, and when does it expire?

Summary for Patent: 8,431,615